Identifying Common Genes Related to Platelet and Immunity for Lung Adenocarcinoma Prognosis Prediction

Abstract

Background: Although 1000s of immune-related and platelet receptor-related genes have been identified in lung adenocarcinoma, their role in prognosis prediction remains unclear.Methods: We downloaded mRNA data from the Cancer Genome Atlas Dataset (TCGA), and GSE68465 or GSE14814 data sets from the Gene Expression Omnibus (GEO) database. Results:The high-risk group's overall survival (OS) time was lower than that of the lowrisk group's in TCGA (p = 1.15e-03). Additionally, the risk score was an independent prognostic survival factor for lung adenocarcinoma patients in TCGA (HR = 2.136, 95%CI = 1.553-2.937, p < 0.001). The model's prognostic performance was verified with two independent GEO cohorts (GSE68465 and GSE14814). We also developed a nomogram and provided free webpage prediction tools. 1 The mechanism of the highrisk group in this risk score may be have been related to somatic mutations and copy number changes. In addition, this risk score can distinguish the prognosis of the other two cancers (ACC, p < 0.001 and KIRP, p < 0.001). Also, among the other seven cancers, the OS prognosis for high and low risk groups show wide variation (p < 0.05). Conclusion:Our research demonstrates that CCNA2 and TGFB2 are potential diagnostic and prognostic biomarkers, as well as therapeutic targets in lung adenocarcinoma (LUAD). We also determined a novel and reliable prognostic score for lung adenocarcinoma prognosis. The online nomogram prediction tool that contains this risk score may also help clinical medical staff.

The Predictive Competing Endogenous RNA Regulatory Networks and Potential Prognostic and Immunological Roles of Cyclin A2 in Pan-Cancer Analysis

“…High expression of CCNA2 was connected with the poor OS in LIHC ( Li et al, 2021a ) and PRAD ( Feng et al, 2021 ). CCNA2 expression was an essential component of the prognostic model in LUAD ( Zhou et al, 2020 ), LUSC ( Gao et al, 2020 ) and KIRC ( Zhan et al, 2021 ).…”

CCNA2 as an Immunological Biomarker Encompassing Tumor Microenvironment and Therapeutic Response in Multiple Cancer Types

“…Some other interesting and relevant discoveries include the significant correlation between CCNA2 expression and MLH1, MSH2, MSH6, PMS2, and EPCAM, suggesting that CCNA2 may be involved in tumor-related developmental processes including signaling, migration, and proliferation [40,41]. Zhou et al found that CCNA2 is a potential diagnostic and prognostic biomarker for LUAD, and CCNA2 expression positively correlated with immunity therapy efficiency in LUAD [42]. Chen et al also confirmed that CCNA2 is involved in hypoxia signature affecting the clinical outcomes and immune microenvironment of ACC [43].…”

Anticancer effects of disulfiram in T-cell malignancies through NPL4-mediated ubiquitin–proteasome pathway

“…8,49,50 The ANAPC1 protein in the ubiquitin-proteasome pathway is a cell cycle-regulating E3 ubiquitin ligase, which promotes cancer progression by controlling mitosis and the G1 phase of the cell cycle, and high ANAPC1 was associated with poor prognosis. 51,52 Furthermore, another ubiquitinproteasome pathway gene, PSMD2, regulates cancer cell proliferation and cell cycle progression by modulating proteasome degradation, which is positively correlated with poor prognosis. 53,54 In this study, the expression levels of ANAPC1 and PSMD2 were decreased…”

“…Therefore, a molecular‐based prognosis model and risk stratification are needed to further improve prediction accuracy for patients with TCL and T‐ALL 8,49,50 . The ANAPC1 protein in the ubiquitin–proteasome pathway is a cell cycle‐regulating E3 ubiquitin ligase, which promotes cancer progression by controlling mitosis and the G1 phase of the cell cycle, and high ANAPC1 was associated with poor prognosis 51,52 . Furthermore, another ubiquitin–proteasome pathway gene, PSMD2, regulates cancer cell proliferation and cell cycle progression by modulating proteasome degradation, which is positively correlated with poor prognosis 53,54 .…”